MannKind Corp. in Westlake Village has partnered with Santa Monica’s GoodRx, an app that allows people to see the best prices for drugs.
For MannKind, which makes inhalable insulin Afrezza, the goal is raise awareness on ways patients can save on their mealtime insulin. The company hopes a connection with GoodRx pushes this type of treatment to the forefront of patient’s minds when they think about alternatives to injectable mealtime insulin.
Through the GoodRx platform, patients will be able to get Afrezza for as low as $15 at the pharmacy with a promoted copay and savings card program.
“Coupled with our innovative direct purchase program and enhanced copay savings card programs, the GoodRx platform will allow us to potentially raise awareness about how patients can better manage the financial burden that comes with living with diabetes,” Michael Castagna, chief executive of MannKind, said in a statement. “We believe that Afrezza is an innovative therapeutic option and that price should not be a barrier to treatment.”
Shares of MannKind (MNKD) closed Monday unchanged at $1.09 on the Nasdaq.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- MannKind Studies Show Afrezza Safe, Effective
- FDA Panel Recommends Approval of MannKind's Afrezza
- CEO Breathes Life Into Inhalable Insulin Maker
- MannKind Eyes Canadian Insulin Producer
- Results Are Another Giant Leap for MannKind
- Life Left in Biotech?
- FDA Could Limit MannKind Inhaler
- MannKind Shares Fall on FDA Delay